An additional regulatory application is also under review in the european union, with a decision expected by the first half of 2026. Regeneron pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (cscc) who are at a high risk of recurrence following surgery and radiation. Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo Review important safety info & full prescribing information including med guide. Cemiplimab is a newer cancer treatment that has brought hope to patients with advanced skin and lung cancers It is part of an exciting group of drugs called immune checkpoint inhibitors, which help the body’s immune system fight cancer more effectively
Cemiplimab is approved by the u.s Food and drug administration (fda) to treat advanced forms of skin cancers, including cutaneous squamous.
OPEN
